MDMA Therapy Shows Promise for Israeli PTSD Sufferers
A groundbreaking study in Israel is exploring the therapeutic potential of MDMA, commonly known as ecstasy, for individuals suffering from Post-Traumatic Stress Disorder (PTSD). Despite its historical association with recreational drug use and its classification as a dangerous substance since 1985, researchers are now investigating MDMA's ability to foster empathy, openness, and trust, which may aid PTSD patients in confronting painful memories.
Israel, with an estimated 625,000 individuals affected by PTSD, has a particular interest in these studies. The economic burden of PTSD on the Israeli economy is projected to reach 100 billion shekels annually, a figure exacerbated by the ongoing conflict. Currently, at least ten studies involving MDMA are underway in Israel, targeting various groups including survivors of the October 7th attacks, ZAKA volunteers, and security personnel.
The study at Mativ, the Israeli Center for Psychotrauma at the Herzog Medical Center, focuses on former security forces personnel. The aim is to gather sufficient evidence to support the FDA's approval of MDMA-assisted psychotherapy for broader use beyond clinical trials. The research highlights the personal experiences of patients and therapists, moving beyond the scientific aspects of how MDMA affects brain activity.
Participants in the Mativ study have reported significant breakthroughs. One former intelligence officer, 'M' (54), described how MDMA helped him process traumatic memories of combat, including witnessing an explosion and the death of a comrade. He experienced a reduction in unexplained physical pain, which he linked to a specific traumatic event, and a significant decrease in guilt. Another participant, Dudi Greenbaum (53), a former special forces officer, found that MDMA allowed him to confront frightening memories with a sense of calm and self-compassion, leading to a reduction in his guilt and a decrease in his medication.
A third participant, 'G' (42), a high-tech professional and former paramedic, used MDMA to process a traumatic incident involving a baby. He experienced visual and auditory hallucinations during the therapy, which he described as a controlled journey through difficult memories, allowing him to process events without being overwhelmed. This therapy has enabled him to feel more in control of his life and reduce his reliance on medical cannabis.
Clinical psychologist Dalia Zivan and psychologist Dr. Anna Harwood-Gross, leading the Mativ trial, explain that MDMA therapy, conducted over several months with both male and female therapists, helps patients differentiate between past trauma and present reality. Unlike other psychedelics that can cause ego dissolution, MDMA promotes connection and openness, allowing patients to engage with traumatic memories safely. The treatment involves a combination of talk therapy and MDMA-assisted sessions, with participants staying overnight after the MDMA session for monitoring. Early results are highly encouraging, with many participants showing a significant reduction in PTSD symptoms, enabling them to return to work and improve their relationships.
